Question special

Personally found it brilliant how the authors designed this study and all the hard work behind it.
As this phase 2 study approaches patients already treated with statins (low and high dose) with or without ezetimibe and most of them on PCSK9 inhibitors (160/160 in SC group and 102/106 in IV group). Given Evinacumab's effectiveness, is it early to start to consider this agent as a promising third line just after statins and PCSK9 inhibitors? I would like to know your thoughts about including evinacumab before ezetimibe, niacin, or Mipomersen in the treatment for hyperlipidemia.